LQDA

Liquidia Corporation Common Stock

$33.94

Current Price

All

AI analysis

Read what the AI thinks of Liquidia Corporation Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

$1.39

P/E

45.7

Data as of Oct 1

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Before the open · Expected EPS: $0.91

Nov 10

Posts

No posts about LQDA yet.

About Liquidia Corporation Common Stock

Liquidia is a drug company that makes Yutrepia, an inhaled powder form of the drug treprostinil. Doctors prescribe it for pulmonary arterial hypertension, which is high blood pressure in the arteries of the lungs. Liquidia earns money by selling Yutrepia to patients with that condition, and it is also developing a second experimental lung drug called L606.